← FDA DRUG APPROVALS

FDA BLA · BLA761152

YARTEMLEA

narsoplimab

Sponsor: OMEROS CORP

APPLICATION
BLA761152
TYPE
BLA
ORIGINAL APPROVAL
2025-12-23
LATEST ACTION
2025-12-23
ROUTE
INTRAVENOUS
DOSAGE FORM
INJECTION
MARKETING STATUS
Prescription

Products

YARTEMLEAPrescription
NARSOPLIMAB-WUUG · INJECTION

Approval history

2025-12-23Type 1 - New Molecular Entity · Original · priorityLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Biologics industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →